LTR Pharma Limited ( (AU:LTP) ) has provided an update.
LTR Pharma Limited announced that Professor Eric Chung will present pivotal clinical trial data for SPONTAN® at the USANZ Annual Scientific Meeting. The data reveals SPONTAN’s significant advantages over existing ED treatments, with a 470% faster absorption rate and comparable bioavailability and safety profile, positioning it as a potential disruptor in the global ED market.
More about LTR Pharma Limited
LTR Pharma is dedicated to enhancing men’s health through the commercialization of an innovative nasal spray treatment for Erectile Dysfunction (ED). Their lead product, SPONTAN®, utilizes intranasal delivery technology of a PDE5 inhibitor for rapid absorption, aiming to improve the spontaneity and enjoyment of sexual experiences.
YTD Price Performance: -24.07%
Average Trading Volume: 653,469
Technical Sentiment Consensus Rating: Strong Buy
Learn more about LTP stock on TipRanks’ Stock Analysis page.